Streetbeat News

MEDS

TRxADE HEALTH, Inc.

https://www.trxadehealth.com

Industry

Medical - Pharmaceuticals

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Open

7.25

Mkt cap

13M

Volume

19K

High

7.70

P/E Ratio

-0.31

52-wk high

44.56

Low

7.06

Div yield

1.25

52-wk low

3.69

Discover Financial Services (DFS) shares rose by 11% in pre-market trading after Capital One Financial Corp (COF) announced plans to acquire DFS in a $35.3 billion all-stock deal, offering a 26% premium over DFS's last closing price. Other stocks showed significant pre-market movements, with notable gainers including AgriFORCE Growing Systems (AGRI) and Shineco, Inc. (SISI), and losers like Universe Pharmaceuticals INC (UPC) and MicroCloud Hologram Inc. (HOLO).

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 1:09 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Trxade Health (MEDS) led the gainers with a 207.2% increase, while RAPT Therapeutics (RAPT) experienced the largest drop among the losers, declining by 67.3%. Other notable movers include Biofrontera (BFRI) with a 206.87% increase and Ocugen (OCGN) rising by 28.54%. The movements reflect significant volatility in the healthcare sector.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 1:05 pm

In Monday's after-market session, several health care stocks showed significant movement. Trxade Health (MEDS) saw a notable increase of 105.3%, while Universe Pharmaceuticals (UPC) experienced a significant decrease of 27.6%. Other stocks such as Iovance Biotherapeutics (IOVA) and Virpax Pharmaceuticals (VRPX) also saw upward movements, whereas companies like Sientra (SIEN) and Femasys (FEMY) faced declines.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 9:30 pm

TRxADE HEALTH announced the sale of assets of its subsidiary, Trxade, Inc., to Micro Merchant Systems for $22.5 million, with a potential additional payout of $7.5 million. This strategic move could significantly impact TRxADE HEALTH's financial position and future operations.

Portfolio Pulse from Charles Gross

February 17, 2024 | 1:54 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. China SXT Pharmaceuticals, Titan Pharma, Trxade Health, Elicio Therapeutics, Nutex Health, and Mineralys Therapeutics were among the gainers with notable percentage increases in their stock prices. Conversely, Jin Medical International, Tenax Therapeutics, InVivo Therapeutics Holdings, HOOKIPA Pharma, ThermoGenesis Holdings, and Exicure were the losers, experiencing substantial declines.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 1:06 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Revance Therapeutics, Eterna Therapeutics, Connect Biopharma Hldgs, Celularity, Trxade Health, and Windtree Therapeutics were among the gainers, with increases ranging from 12.19% to 16.5%. On the downside, GRI Bio, Sharps Technology, Biofrontera, Kiora Pharmaceuticals, Cadrenal Therapeutics, and Corbus Pharmaceuticals experienced declines between 9.04% and 31.8%.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:06 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. NeuroBo Pharmaceuticals (NRBO) led the gainers with a 55.3% increase, while Revelation Biosciences (REVB) saw the largest decrease among the losers, dropping 62.6%. Other notable movers included Kiora Pharmaceuticals (KPRX) and Celularity (CELU) with substantial gains, and InVivo Therapeutics Holdings (NVIV) and Bullfrog AI Holdings (BFRG) with notable losses.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 5:31 pm

TRxADE HEALTH, Inc. (NASDAQ:MEDS) filed its Q3 10-Q report for the period ending September 30, 2023. The company previously received a notice of noncompliance from Nasdaq due to the late filing but believes it has now regained compliance with the filing of its Form 10-Q.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 2:17 pm

TRxADE Health has received a notice from Nasdaq for not complying with the listing rules due to a delay in filing its quarterly report (Form 10-Q). The company has 60 days to submit a plan to regain compliance and may receive up to 180 days from the original due date to file the report and comply with Nasdaq's rules. TRxADE Health is working to complete and file the Form 10-Q as soon as possible.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 6:56 am

TRxADE Health received a notice from Nasdaq on November 21 indicating non-compliance with the timely filing requirement for continued listing due to the delayed filing of Form 10-Q. The company is working to file the required form as soon as possible to regain compliance with Nasdaq's listing rule, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 5:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.